The acceptance emails landed and the world went quiet, as everyone became focused. The noise of speculation and debate that had run for weeks dropped, as everyone turned their attention to the day of departure.

One hundred people began making arrangements.

The logistics were different for each of them. Some had conditions that made travel planning straightforward. Others needed medical equipment coordinated, medications documented, accessible transport confirmed from their front door to the departure airport. A few needed help filling out the paperwork because the hands that had always done those things no longer worked the way they once had.

Most of them decided to bring someone.

The acceptance email had made provision for a caretaker — one person, verified, traveling alongside the volunteer for the duration. The official purpose was support. The actual reason most families settled on one person over another was simpler: who did the volunteer trust most, and who could hold themselves together through whatever came next.

Some families had arguments about it. Gentle arguements, mostly. Everyone wanted to come and everyone understood why only one could.

The chosen ones began their own preparations alongside the volunteers. What to pack for a month or months on the moon. What questions to write down before they forgot them. How to explain to the people they were leaving behind where they were going and why.

For most volunteers, the days before departure moved between nervousness and anticipation in a rhythm that was hard to settle. They had been told what was coming. They had read the protocols. They had watched the footage the staff had posted — the rooms, the common space, the green running along the base level — and had tried to map themselves into those images.

For the guardian of the volunteer who had not opened their eyes in months, the days moved differently.

They packed carefully and did not let themselves think too far ahead. One step at a time, until the step that mattered.

***

The volunteers weren’t the only ones making preparations. The observers were doing the same, as they were all being briefed by their governments and organisations, while they also made preparations for their departure.

The WHO briefing occupied a conference room on the fourth floor of the Regional Office for Europe in Geneva, with a view of the Palais des Nations visible through the window that nobody looked at.

The three-person delegation was Dr. Amara Diallo, a Senegalese physician. Alongside her was Dr. Henrik Sorensen, a Danish public health specialist. And Counsel Miriam Stein, a Swiss international lawyer whose role was to observe the trial’s framework against the existing architecture of international health law and document what fit, what didn’t, and what had no category yet.

The WHO department heads on the other side of the table represented the institution’s primary stakes in the trial. The Director of Health Systems. The lead on the Global Initiative for Emergency and Essential Surgical Care. The head of the Mental Health and Substance Use department, who had been the most vocal internally about the significance of the trial’s mental health volunteer categories. And the Director-General’s chief of staff, whose presence signaled that whatever happened in this room carried institutional weight above the department level.

The Director of Health Systems opened the briefing.

"I want to begin by stating something that should be obvious but needs to be said clearly before we go further," she said. "What you are being sent to observe is not a clinical trial in any sense that our existing frameworks were designed to evaluate. The WHO has observer frameworks for pharmaceutical trials, for device trials, for surgical procedure evaluations. We have protocols for observing trials conducted in low-resource environments, in conflict zones, in circumstances where standard oversight is compromised. None of those frameworks apply here in any complete sense." She paused. "You are going to a facility on the moon to observe a platform technology treating one hundred volunteers across every major disease category simultaneously, conducted by an organization that operates outside every regulatory structure we have authority over."

Dr. Diallo nodded. She had read every public Nova Technologies document since the first announcement. She had expected the briefing to begin exactly this way.

"Your mandate has three primary components," the Director continued. "First, clinical observation, which is documenting what you witness on the medical floor within your designated access scope, the monitoring data you are given real-time access to, and the interactions between staff and volunteers that you are permitted to observe. Second, geographic equity verification — confirming that the volunteer pool reflects the distribution commitment made in the public announcements, specifically the fifteen percent regional cap, and that the distribution holds in practice rather than only on paper. Third, framework documentation — recording how the trial’s consent procedures, data privacy protocols, and withdrawal rights function in practice against what was publicly stated."

She looked at Stein. "The legal documentation is the component with the longest reach. What you write in those observation notes becomes part of the institutional record from which any future international health law framework for off-world medical research will eventually be constructed. That work doesn’t exist yet. You are contributing to its foundation."

Stein had her copy of the observer framework open with forty-two marked lines. She had been thinking about the jurisdictional gap since the observer confirmation announcement had named the WHO. "We are being asked to evaluate a trial we have no authority over, conducted in a location no international body has jurisdiction over, by an organization that has demonstrated it operates on its own terms regardless of external frameworks." She looked up. "What is the institutional position on that?"

"The institutional position," the Director of Health Systems said, "is that our presence there is more valuable than our absence, and that the documentation we produce has more long-term impact than any authority we could theoretically assert and practically not enforce." She held Stein’s gaze. "We are not pretending we have leverage we don’t have. We are using the access we were given."

The head of Mental Health and Substance Use had been quiet until now. "The mental health volunteer categories concern me more than any other aspect of the trial," she said. "Treatment-resistant PTSD. Major depressive disorder. Substance use disorders. These are conditions where outcome measurement is not objective in the way that spinal cord regeneration is objective. A volunteer walking after a complete spinal cord injury is an unambiguous result. A volunteer reporting improvement in treatment-resistant depression is a more complex picture. What does the monitoring data look like for those cases? How does the system measure neurological intervention? We don’t know, and we won’t know until you’re in that room watching it happen."

"Which is precisely why your background informs this delegation," the Director said. "Document what you see without filtering it through frameworks that don’t apply. If the monitoring data for a mental health case shows you something you can’t interpret with existing tools, write down exactly what you saw and bring it back. The interpretation happens here, with time and with the full picture."

Dr. Sorensen looked at the geographic distribution section of the briefing document. "The volunteers from regions with historically limited healthcare access — when we observe their outcomes, we are potentially watching the first demonstration of what this technology does for populations the existing medical system has largely failed. That observation has implications that extend well beyond this trial." He set the document down. "I want to make sure the delegation’s reporting gives that appropriate weight."

The briefing continued for two hours. Each department head worked through the aspects of the trial most relevant to their mandate. Questions were asked and answered where answers existed, and the Director was consistent about the ones that didn’t.

At the end, she looked at the three delegates across the table.

"You are going to witness things that the global health community has been working toward for generations," she said. "Conditions that have defined and diminished and ended lives across every country on this planet, being addressed in ways we could not have designed ourselves and could not have predicted. You are also going to witness a framework for medical research that exists entirely outside the structures the WHO was built to work within." She paused. "Both of those things are true simultaneously. Your job is to observe both with equal clarity and bring back a picture that is honest about what this is — not what we hoped it would be, and not what we feared it might be. What it actually is."

She closed the briefing document.

"The world is going to ask the WHO what it witnessed. What you write in those notes is what we will tell them."

Dr. Diallo, Dr. Sorensen, and Counsel Stein left the building together, walked out into the Geneva afternoon, and stood on the pavement for a moment without speaking.

The Palais des Nations was visible above the tree line to the north. Flags from every member state ran along its approach, as they always had, marking the accumulated weight of everything the international community had built across a century of trying to manage the world’s problems together.

Dr. Diallo looked at them for a moment.

Then she looked up, past the flags and the tree line and the pale Swiss sky, toward something that wasn’t visible from here but was there nonetheless.

"Six days," she said.

They walked to their respective cars and began their own preparations.